Probucol and ticlopidine: effect on platelet and monocyte activation markers in hyperlipidemic patients with and without type 2 diabetes
- 1 June 2004
- journal article
- clinical trial
- Published by Elsevier in Atherosclerosis
- Vol. 174 (2) , 329-335
- https://doi.org/10.1016/j.atherosclerosis.2004.01.027
Abstract
No abstract availableKeywords
This publication has 49 references indexed in Scilit:
- Probucol preserves endothelial function by reduction of the endogenous nitric oxide synthase inhibitor levelBritish Journal of Pharmacology, 2002
- α-tocopherol and probucol reduce autoantibody titer to MDA-LDL in hypercholesterolemic rabbitsFree Radical Biology & Medicine, 2001
- Flow cytometric analysis of platelet activation markers CD62P and CD63 in patients with coronary artery diseaseEuropean Journal of Clinical Investigation, 1996
- Malondialdehyde-modified low density lipoproteins in patients with atherosclerotic disease.Journal of Clinical Investigation, 1995
- Distribution of immunoreactive malondialdehyde-modified low-density lipoprotein in human serumBiochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, 1994
- Preservation of Endothelium-Dependent Relaxation in Atherosclerotic Rabbit Aorta by ProbucolJournal of Cardiovascular Pharmacology, 1993
- The pathogenesis of atherosclerosis: a perspective for the 1990sNature, 1993
- Single risk factor intervention may be inadequate to inhibit atherosclerosis progression when hypertension and hypercholesterolemia coexist.Hypertension, 1991
- Inhibition of IL-1β expression in THP-1 cells by probucol and tocopherolAtherosclerosis, 1991
- Leukocyte and platelet function and eicosanoid production in subjects with hypercholesterolaemiaAtherosclerosis, 1990